CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II, Randomized, Double-blind, Placebo-controlled Study of Myrosinase-enriched Glucoraphanin, a Sulforaphane Precursor System, in Autism Spectrum Disorder

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02909959
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:41.317429+00:00
Published At: 2020-05-15T00:00:00+00:00
Record Updated At: 2020-06-04
Results Posted At: 2020-05-15
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Autism Spectrum Disorder", "Autistic Disorder", "Neurodevelopmental Disorder", "Childhood Developmental Disorders, Pervasive"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2020-06-04"
protocolSection.identificationModule.nctId: "NCT02909959"
protocolSection.identificationModule.officialTitle: "A Phase II, Randomized, Double-blind, Placebo-controlled Study of Myrosinase-enriched Glucoraphanin, a Sulforaphane Precursor System, in Autism Spectrum Disorder"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2020-05-15"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.